Last update 23 Oct 2025

Pembrolizumab/Quavonlimab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
quavonlimab/pembro, MK 1308A, MK-1308A
Target
CTLA4 x PD-1
Action
inhibitors
Mechanism
CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors), PD-1 inhibitors(Programmed cell death protein 1 inhibitors)
Therapeutic Areas
NeoplasmsUrogenital DiseasesDigestive System Disorders+ [2]
Active Indication
Locally Advanced Clear Cell Renal Cell CarcinomaMicrosatellite instability-high colorectal cancerAdvanced Hepatocellular Carcinoma+ [3]
Inactive Indication-
Originator Organization
Merck Sharp & Dohme Corp.Merck Sharp & Dohme Corp.
Active Organization
Merck Sharp & Dohme Corp.Merck Sharp & Dohme Corp.MSD R&D (China) Co. Ltd.MSD R&D (China) Co. Ltd.Merck Sharp & Dohme LLC
Inactive Organization
Merck & Co., Inc.Merck & Co., Inc.
License Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Related

7
Clinical Trials associated with Pembrolizumab/Quavonlimab
NCT04938817
/ RecruitingPhase 1/2
A Phase 1b/2 Study to Evaluate the Efficacy and Safety of Investigational Agents as Monotherapy or in Combination With Pembrolizumab for the Treatment of Participants With PD-1/L1-refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy (KEYNOTE-B98)
CTR20211132
/ CompletedPhase 1
在晚期实体瘤受试者中开展的MK-1308联合帕博利珠单抗的I / II期、开放性、多组、多中心研究
[Translation] A Phase I/II, Open-label, Multi-Group, Multi-Center Study of MK-1308 in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors
NCT04895722
/ Active, not recruitingPhase 2
A Phase 2, Multicenter, Multi Arm, Study to Evaluate MK-1308A (Co-formulated Quavonlimab (MK-1308)/Pembrolizumab) Versus Other Treatments in Participants With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer: (MK-1308A-008)
100 Clinical Results associated with Pembrolizumab/Quavonlimab
Login to view more data
100 Translational Medicine associated with Pembrolizumab/Quavonlimab
Login to view more data
100 Patents (Medical) associated with Pembrolizumab/Quavonlimab
Login to view more data
100 Deals associated with Pembrolizumab/Quavonlimab
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Locally Advanced Clear Cell Renal Cell CarcinomaPhase 3
United States
Merck Sharp & Dohme Corp.Merck Sharp & Dohme Corp.
14 Apr 2021
Locally Advanced Clear Cell Renal Cell CarcinomaPhase 3
China
Merck Sharp & Dohme Corp.Merck Sharp & Dohme Corp.
14 Apr 2021
Locally Advanced Clear Cell Renal Cell CarcinomaPhase 3
Japan
Merck Sharp & Dohme Corp.Merck Sharp & Dohme Corp.
14 Apr 2021
Locally Advanced Clear Cell Renal Cell CarcinomaPhase 3
Australia
Merck Sharp & Dohme Corp.Merck Sharp & Dohme Corp.
14 Apr 2021
Locally Advanced Clear Cell Renal Cell CarcinomaPhase 3
Brazil
Merck Sharp & Dohme Corp.Merck Sharp & Dohme Corp.
14 Apr 2021
Locally Advanced Clear Cell Renal Cell CarcinomaPhase 3
Canada
Merck Sharp & Dohme Corp.Merck Sharp & Dohme Corp.
14 Apr 2021
Locally Advanced Clear Cell Renal Cell CarcinomaPhase 3
Chile
Merck Sharp & Dohme Corp.Merck Sharp & Dohme Corp.
14 Apr 2021
Locally Advanced Clear Cell Renal Cell CarcinomaPhase 3
Colombia
Merck Sharp & Dohme Corp.Merck Sharp & Dohme Corp.
14 Apr 2021
Locally Advanced Clear Cell Renal Cell CarcinomaPhase 3
Croatia
Merck Sharp & Dohme Corp.Merck Sharp & Dohme Corp.
14 Apr 2021
Locally Advanced Clear Cell Renal Cell CarcinomaPhase 3
Czechia
Merck Sharp & Dohme Corp.Merck Sharp & Dohme Corp.
14 Apr 2021
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT04740307 (KEYSTEP-004, ASCO_GI2024)
ManualManual
Phase 2
Advanced Hepatocellular Carcinoma
First line
115
coformulation of quavonlimab and pembro plus lenva
(advanced hepatocellular carcinoma (HCC))
vucwdciqor | lwmdffrcuw(owhytmqthw) = utydgumzui ndbjldftmz (azzwugnaex, 28.5 - 46.9)
View more
Positive
18 Jan 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
view full example data
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free